Sign inJoin waitlistJoin the waitlist

JH

James Harding

Regional Director, Early Drug Development, Gastrointestinal Oncology · New York Presbyterian Hospital

Credentials: · · · · ·

History

New York Presbyterian Hospital
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
2010–2013
New York Presbyterian Hospital
2007–2010
Albert Einstein College of Medicine
2003–2007

Research

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Nature Medicine · 2017 · 2,750 citations
OncoKB: A Precision Oncology Knowledge Base
JCO Precision Oncology · 2017 · 2,318 citations
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
The Lancet Oncology · 2022 · 997 citations

GA
Ghassan Abou-Alfa
74 papers
WJ
William Jarnagin
44 papers
EO
Eileen O'Reilly
42 papers
MD
Michael D'Angelica
28 papers
AW
Alice Wei
27 papers
Vinod Balachandran
26 papers
AC
Andrea Cercek
25 papers
David Solit
23 papers
KS
Kevin Soares
23 papers · 1 as a fellow
PK
Peter Kingham
23 papers
JD
Jeffrey Drebin
19 papers
DK
Danny Khalil
17 papers

Clinical trials

A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer
Principal investigator · Completed · Early phase 1
Memorial Sloan Kettering Cancer Center
2017–2026
Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2015–2021